肥胖与前列腺癌的关联及作用机制研究进展
Research Progress on the Association and Mechanism between Obesity and Prostate Cancer
DOI: 10.12677/acm.2024.1441248, PDF,    科研立项经费支持
作者: 热娜古丽·艾海提*, 安恒庆#：新疆医科大学第一附属医院泌尿中心，新疆 乌鲁木齐
关键词: 前列腺癌；肥胖；胰岛素样生长因子；脂肪因子；炎症；Prostate Cancer； Obesity； IGF； Adipocytokines； Inflammation
摘要: 前列腺癌是男性最常见的泌尿生殖系统肿瘤，近年来与肥胖的发病率同步上升，引发关注。肥胖增加前列腺癌患者疾病发展、复发风险，加剧治疗相关不良反应，加速转移和激素抵抗，提高全因和特异性死亡率。尽管肥胖与前列腺癌的关联复杂，目前暂无定论，但多项研究指向肥胖对晚期前列腺癌的负面影响。肥胖可能通过胰岛素和胰岛素生长因子途径、性激素浓度、脂肪因子信号和炎症反应等途径与前列腺癌发生联系，但具体机制尚未明确。本文综述了肥胖与前列腺癌的关联及作用机制的研究进展。
Abstract: Prostate cancer is the most common tumor of the male urogenital system. In recent years, the incidence of prostate cancer and obesity has increased synchronously, which has attracted attention. Obesity increases the risk of disease progression and recurrence in prostate cancer patients, aggravates adverse reactions related to treatment, accelerates metastasis and hormone resistance, and increases all-cause and specific mortality. Although the association between obesity and prostate cancer is complex and there is no final conclusion at present, many studies point to the negative impact of obesity on advanced prostate cancer. Obesity may be associated with prostate cancer through insulin and insulin growth factor pathways, sex hormone concentrations, adipokines signaling, and inflammatory reactions, but the specific mechanism is not yet clear. This article reviews the research progress on the association and mechanism between obesity and prostate cancer.
文章引用：热娜古丽·艾海提, 安恒庆. 肥胖与前列腺癌的关联及作用机制研究进展[J]. 临床医学进展, 2024, 14(4): 1941-1946. https://doi.org/10.12677/acm.2024.1441248

参考文献

[1] Langlais, C.S., Cowan, J.E., Neuhaus, J., et al. (2019) Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiology, Biomarkers & Prevention, 28, 1917-1925. [Google Scholar] [CrossRef] 
[2] 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13(3): 63-69.
[3] Balogh, E., Patlak, M. and Nass, S.J. (2018) Incorporating Weight Management and Physical Activity throughout the Cancer Care Continuum: Proceedings of a Workshop. National Academies Press, Washington DC. [Google Scholar] [CrossRef] 
[4] Vidal, A.C. and Freedland, S.J. (2017) Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. European Urology, 72, 78-83. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会内分泌学分会肥胖学组. 中国成人肥胖症防治专家共识[J]. 中华内分泌代谢杂志, 2011, 27(9): 711-717.
[6] Enehan, A.G., Tyson, M., Egger, M., et al. (2008) Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies. Lancet, 371, 569-578. [Google Scholar] [CrossRef] 
[7] Wright, M.E., Chang, S.C., Schatzkin, A., et al. (2007) Prospective Study of Adiposity and Weight Change in Relation to Prostate Cancer Incidence and Mortality. Cancer, 109, 675-684. [Google Scholar] [CrossRef] [PubMed]
[8] Pernar, C.H., Ebot, E.M., Wilson, K.M. and Mucci, L.A. (2018) The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 8, a030361. [Google Scholar] [CrossRef] [PubMed]
[9] Freedland, S.J., Bañez, L.L., Sun, L.L., Fitzsimons, N.J. and Moul, J.W. (2009) Obese Men Have Higher-Grade and Larger Tumors: An Analysis of the Duke Prostate Center Database. Prostate Cancer and Prostatic Diseases, 12, 259-263. [Google Scholar] [CrossRef] [PubMed]
[10] Bae, J.C., Cho, N.H., Kim, J.H., et al. (2020) Association of Body Mass Index with the Risk of Incident Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality: A Community-Based Prospective Study. Endocrinology and Metabolism, 35, 416-424. [Google Scholar] [CrossRef] 
[11] Vidal, A.C., Howard, L.E., De Hoedt, A., et al. (2018) Obese Patients with Castrajtion-Resistant Prostal Te Cancer May Be at a Lower Risk of All-Cause Mortality: Resu Ults from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. BJU International, 122, 76-82. [Google Scholar] [CrossRef] [PubMed]
[12] Cao, Y. and Ma, J. (2011) Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: A Systematic Review and Meta-Analysis. Cancer Prevention Research, 4, 486-501. [Google Scholar] [CrossRef] 
[13] Gbenou, G.C.M., Peltier, A., Schulman, C.C., et al. (2016) Increased Body Mass Index as a Risk Factor in Localized Prostate Cancer Treated by Radical Prostatectomy. Urologic Oncology: Seminars and Original Investigations, 34, 254.e1-254.e6. [Google Scholar] [CrossRef] [PubMed]
[14] Goris Gbenou, M.C., Peltier, A., Schulma, N.C.C., et al. (2016) Increased Bodymassin Dex as a Riskfactor in Localized Prostate Cancer Treated by Radical Prostatectomy. Urologic Oncology: Seminars and Original Investigations, 34, 254.e1-254.e6. [Google Scholar] [CrossRef] [PubMed]
[15] 杨云开, 胡毓祺, 王晶运, 等. 前列腺根治术前肥胖相关的生化指标对前列腺癌患者预后的意义[J]. 临床泌尿外科杂志, 2022, 37(1): 42-46.
[16] Keto, C.J., Aronson, W.J., Terris, M.K., et al. (2012) Obesity Is Associated with Castration-Resistant Disease and Metastasis in Men Treated with Androgen Deprivation Therapy after Radical Prostatectomy: Results from the SEARCH Database. BJU International, 110, 492-498. [Google Scholar] [CrossRef] 
[17] Federico, G., Alessandro, T., Andrea, P., et al. (2022) Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue. Uro, 2, 270-276. [Google Scholar] [CrossRef] 
[18] Dipti, G., Katherine, C.L., Can, J.Y., et al. (2018) Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer. Journal of Oncology Practice, 14, 580-587. [Google Scholar] [CrossRef] 
[19] Di Bella BS, C.M., et al. (2020) Abdominal and Pelvic Adipose Tissue Distribution and Risk of Prostate Cancer Recurrence after Radiation Therapy. The Prostate, 80, 1244-1252. [Google Scholar] [CrossRef] [PubMed]
[20] Jochems, S.H.J., Fritz, J., Häggström, C., Stattin, P. and Stocks, T. (2023) Prediagnostic Markers of Insulin Resistance and Prostate Cancer Risk and Death: A Pooled Study. Cancer Medicine, 12, 13732-13744. [Google Scholar] [CrossRef] [PubMed]
[21] 刘斌, 匡安仁. MAPK/ERK和PI3K/Akt信号通道的基因变异与甲状腺癌的发生发展及诊治[J]. 生物医学工程学杂志, 2012, 29(6): 1221-1225.
[22] Carolin, S, Jochen, R, Sebastian, M, et al. (2022) Insulin-Like Growth Factor-1 Influences Prostate Cancer Cell Growth and Invasion Through An Integrin α3, α5, αV, and β1 Dependent Mechanism. Cancers, 14, Article 363. [Google Scholar] [CrossRef] [PubMed]
[23] 冯上志. 外泌体蛋白IGFBP3对前列腺癌细胞生物学行为和肿瘤微环境的影响[D]: [硕士学位论文]. 赣州: 赣南医学院, 2023.
[24] Nickerson, T., Chang, F., Lorimer, D., et al. (2001) In Vivo Progression of LAPC9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-Like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR). Cancer Research, 61, 6276-6280.
[25] 宋新达, 王建业. 睾酮水平和前列腺癌关系的研究进展[J]. 当代医学, 2020, 26(28): 192-194.
[26] 张高辉, 叶兴龙. 雄激素受体参与去势抵抗性前列腺癌发生机制的研究进展[J]. 吉林医药学院学报, 2023, 44(2): 113-116.
[27] 王振位, 聂黎虹, 杨博雅, 等. 雄激素抑制PI3K/AKT/AR通路促进前列腺癌C4-2B细胞凋亡[J]. 宁夏医科大学学报, 2022, 44(3): 253-259.
[28] 梁之娴, 张琚. 去势耐受前列腺癌中雌雄激素对芳香化酶表达的影响及芳香化酶启动子成分的改变[J]. 南开大学学报(自然科学版), 2022, 55(4): 38-42.
[29] 熊天宇, 牛亦农. 前列腺周围脂肪组织影响前列腺癌发展的机制[J]. 首都医科大学学报, 2023, 44(3): 457-462.
[30] Sruthi, K.K., Sirisha, N. and Ramesh, U. (2023) Tumor Protein D52 (Isoform 3) Induces NF-κB-STAT3 Mediated EMT Driving Neuroendocrine Differentiation of Prostate Cancer Cells. The International Journal of Biochemistry Cell Biology, 166, Article ID: 106493.
[31] Gheorghe, D.C., Stanciu, M.M., Zamfirescu, A., et al. (2021) TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis. Cancers, 13, Article 3609. [Google Scholar] [CrossRef] [PubMed]
[32] Adesunloye, B.A. (2021) Mechanistic Insights into the Link between Obesity and Prostate Cancer. International Journal of Molecular Sciences, 22, Article 3935. [Google Scholar] [CrossRef] [PubMed]
[33] 刘鑫, 邢雷. 肿瘤相关脂肪细胞因子与前列腺癌的相关性研究进展[J]. 云南医药, 2018, 39(6): 544-547.

为你推荐